RecruitingNCT07528014

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1


Sponsor

Salma Health, Inc.

Enrollment

5,000 participants

Start Date

Mar 25, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Adults (≥18 years) of any gender identity presenting for care with a depressed mood.
  • Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care.
  • Able to provide informed consent and comply with all study requirements.

Exclusion Criteria1

  • Any condition deemed by the investigator to preclude safe participation in study assessments.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

Salma Health

La Jolla, California, United States

Salma Health

Laguna Hills, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07528014


Related Trials